Ibrutinib-Mediated Inhibition of cGVHD Pathogenic Pre-Germinal Center B-Cells and Follicular Helper Cells While Preserving Immune Memory and Th1 T-Cells
Year: 2018
Type: article
Abstract: Background: Chronic graft-versus-host disease (cGVHD) is a life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT). Recent studies point to the involvement of T and B cells in the pathogenesis of cGVHD. Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and interleukin-2-inducible T-cell kinase (ITK). In a phase 1b/2 study, ibrutinib showed substantial clinical benefit in patients with cGVHD that had failed frontline therapy (Miklos et al. ASH 2016).
Authors: Bita Sahaf, Dmitry Tebaykin, Melissa Hopper, Patricia Cheung, Fabiola Bittencourt, Corey Cutler, Mukta Arora, Edmund K. Waller, Madan Jagasia, Iskra Pusic, Mary E. Flowers, Aaron C. Logan, Samantha Jaglowski, Jason Lih, Isabelle Solman, Indu D. Lal, Lori Styles, John S. Hill, Danelle F. James, Sean Bendall, Jason Dubovsky, David Miklos
Institutions: Stanford Medicine, Stanford University, Pharmacyclics (United States), Dana-Farber Cancer Institute, University of Minnesota, Emory University, Winship Cancer Institute, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Washington University in St. Louis, Fred Hutch Cancer Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2787874829